Market closed
ACADIA Pharmaceuticals/$ACAD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Ticker
$ACAD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
654
Website
ACAD Metrics
BasicAdvanced
$2.5B
10.90
$1.36
0.43
-
Price and volume
Market cap
$2.5B
Beta
0.43
52-week high
$20.68
52-week low
$13.40
Average daily volume
1.7M
Financial strength
Current ratio
2.376
Quick ratio
2.18
Long term debt to equity
5.737
Total debt to equity
7.095
Management effectiveness
Return on assets (TTM)
5.44%
Return on equity (TTM)
38.89%
Valuation
Price to earnings (TTM)
10.904
Price to revenue (TTM)
2.566
Price to book
3.37
Price to tangible book (TTM)
4.03
Price to free cash flow (TTM)
15.634
Growth
Revenue change (TTM)
31.85%
Earnings per share change (TTM)
-463.53%
3-year revenue growth (CAGR)
25.54%
3-year earnings per share growth (CAGR)
9.15%
What the Analysts think about ACAD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
ACAD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ACAD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ACAD News
AllArticlesVideos
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 weeks ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals (ACAD) has a market cap of $2.5B as of April 25, 2025.
What is the P/E ratio for ACADIA Pharmaceuticals stock?
The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 10.9 as of April 25, 2025.
Does ACADIA Pharmaceuticals stock pay dividends?
No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next ACADIA Pharmaceuticals dividend payment date?
ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.
What is the beta indicator for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.